SynthesisProstate cancer and prostatic diseases2024
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs).
Synthesis in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Pathologic failure and salvage approaches following focal therapy for localized prostate cancer.The Canadian journal of urology · 2026Article
- Performance of PI-FAB and TARGET scoring systems in post focal therapy mpMRI surveillance.Research square · 2026Article
- Focal Therapy for Prostate Cancer: State of the Art, Physical Principles, Potentials, and Challenges.Cancers · 2026Review
- Medicolegal landscape of prostate cancer ablative therapy: a national legal database analysis of malpractice claims (1970-2024).International urology and nephrology · 2026Article
- Hemigland cryoablation versus high-intensity focused ultrasound for localized prostate cancer: a propensity-weighted comparison of functional and oncologic outcomes.World journal of urology · 2026Article
- Functional outcomes and toxicity following focal low-dose-rate brachytherapy for low-intermediate risk prostate cancer.BJUI compass · 2026Article
- Focal irreversible electroporation for the treatment of localised prostate cancer: a systematic review.Translational andrology and urology · 2025Review
- Multimodality focal therapy for prostate cancer: outcome of theProstate international · 2025Article
- Hydrodissection using 10% dextrose before focal therapy of prostate cancer: Initial experience.BJUI compass · 2025Article
- Epidemiology, diagnosis and treatment of anterior prostate cancer.Nature reviews. Urology · 2025Review
- Transperineal Focal Laser Ablation of the Prostate for Prostate Cancer: A Systematic Review of the Literature.Cancers · 2025Review
- Navigating Focal Therapy for Prostate Cancer: Contemporary Perspectives and Future Trajectories in the Canadian Context.Journal of endourology · 2025Review
- Retzius-sparing radical prosatectomy: First 200 Australian cases.BJUI compass · 2025Article
- Functional outcomes of single-session holmium laser enucleation of the prostate and high-intensity focused ultrasound in management of patients with prostate cancer and enlarged prostate: results from a pilot study.World journal of urology · 2024Article
- A narrative clinical trials review in the realm of focal therapy for localized prostate cancer.Translational cancer research · 2024Review
- High-intensity focused ultrasound strategies for treating prostate cancer.Asian journal of andrology · 2024Review
- Article
- Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy.World journal of urology · 2024Article
- One-year Follow-up Results of Transperineal Biopsy For Patients Undergoing Irreversible Electroporation Treatment in Localized Prostate Cancer.Urology research & practice · 2023Article
- Irreversible electroporation as a focal therapy for localized prostate cancer: A systematic review.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFocal therapy (FT) is a promising alternative with curative intent for Low- to Intermediate-risk localized Prostate Cancer (PCa), claiming better functional outcomes and safety profile than standard whole-gland treatments. Ten different FT modalities have been described in the literature. The objective of our narrative review is to evaluate the safety profile and functional outcomes of these different modalities and the current most used tools of assessment for those outcomes. MATERIAL AND
methodsLiterature search was performed on 21st February 2023 using PubMed, EMBASE, and Scopus, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA). Articles reporting whole-gland treatments were excluded. All articles reporting functional outcomes were included.
resultsOne-hundred-seven studies, reporting data on 6933 patients, were included (26 on High Intensity Focal Ultrasound, 22 on Focal Cryotherapy, 14 on Irreversible Electroporation, 11 on Focal brachytherapy, 10 on Focal Laser Ablation, 8 on Photodynamic Therapy, 3 on Microwave ablation, 3 on Robotic Partial Prostatectomy, 2 on bipolar Radio Frequency Ablation, 1 on Prostatic Artery Embolization, and 7 studies comparing different FTs). Post-operative pad-free rate ranged between 92.3-100%. Greater heterogeneity exists considering the Change in Erectile Function, with Changing in Erectile function- rates ranging between 0-94.4% (Cryotherapy). The most used Patient-Reported Outcome Measures (PROMs) were the International Prostate Symptom Score and the International Index of Erectile Function for incontinence/urinary function and potency, respectively. The most common reported complications were hematuria, infections, and urethral strictures, with rates widely ranging among different treatments. The Clavien-Dindo Classification was the most used (40/88 papers) to describe adverse events.
conclusionFT is a promising treatment for localized PCa, achieving excellent results in terms of safety and functional outcomes. There is a wide heterogeneity in the definition of PROMS and time of collection between studies. High quality comparative studies with standard treatments are needed to reinforce these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.